The clinical trial landscape of bispecific antibodies in non-small cell lung cancer: mechanistic trends and developmental strategies

Zunyuan Li, Xiyu Wang, Qin Shi, Yuhong Guo, Guirong Dong, Zhidan Liu

Open source

DOI
10.3389/fphar.2026.1901850
Published
2026-09-03
Container
Frontiers in Pharmacology
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.1901850,
  title = {The clinical trial landscape of bispecific antibodies in non-small cell lung cancer: mechanistic trends and developmental strategies},
  author = {Zunyuan Li and Xiyu Wang and Qin Shi and Yuhong Guo and Guirong Dong and Zhidan Liu},
  year = {2026},
  journal = {Frontiers in Pharmacology},
  doi = {10.3389/fphar.2026.1901850},
  url = {https://doi.org/10.3389/fphar.2026.1901850}
}

RIS

TY  - JOUR
TI  - The clinical trial landscape of bispecific antibodies in non-small cell lung cancer: mechanistic trends and developmental strategies
AU  - Zunyuan Li
AU  - Xiyu Wang
AU  - Qin Shi
AU  - Yuhong Guo
AU  - Guirong Dong
AU  - Zhidan Liu
PY  - 2026
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2026.1901850
UR  - https://doi.org/10.3389/fphar.2026.1901850
ER  - 

APA

Li, Z., Wang, X., Shi, Q., Guo, Y., Dong, G., & Liu, Z. (2026). The clinical trial landscape of bispecific antibodies in non-small cell lung cancer: mechanistic trends and developmental strategies. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2026.1901850

Source records